

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

1. (Currently Amended) A method for inhibiting KDR/Flk-1 signal transduction in endothelial cells, which comprises contacting the cells with a monoclonal antibody which specifically recognizes ~~using a substance which inhibits binding of a signal transduction molecule to~~ 1175-tyrosine phosphorylated KDR/Flk-1 or an antibody fragment thereof.

2. (Currently Amended) A method for inhibiting cell growth of endothelial cells, which comprises contacting the cells with a monoclonal antibody which specifically recognizes ~~using a substance which inhibits binding of a signal transduction molecule to~~ 1175-tyrosine phosphorylated KDR/Flk-1 or an antibody fragment thereof.

Claims 3-9 (Canceled).

10. (Currently Amended) The method according to any one of claims 1 to 2, wherein the ~~signal transduction molecule is~~ monoclonal antibody inhibits binding of phospholipase C- γ (PLC- γ) to 1175-tyrosine phosphorylated KDR/Flt-1.

Claims 11-42. (Cancelled)

43. (New) The method according to any one of claims 1 to 2, wherein the monoclonal antibody is a humanized anti-1175-tyrosine phosphorylated KDR/Flk-1

antibody which binds to an epitope which is recognized by an antibody produced by a hybridoma KM3035 (FERM BP-7729).

44. (New) The method according to claim 43, wherein the humanized anti-1175-tyrosine phosphorylated KDR/Flk-1 antibody is a human chimeric antibody or a human complementarity-determining region (CDR)-grafted antibody.